报告「分母」数据对卵巢癌基准制定和质量标准至关重要
该研究回顾性分析了区域癌症中心593例晚期卵巢癌患者77个月的总生存,并按治疗分层发现中位总生存从仅接受初次减瘤术的54.5个月降至总患者队列的30.2个月;系统检索文献仅11%研究报告了分母描述。作者认为发表结局应常规纳入报告中心管理的所有女性结局,以利于基准制定和质量保证。
要点
- 中位总生存随纳入人群扩大而递减,从仅初次减瘤术的54.5个月降至总患者队列的30.2个月。
- 手术组与总患者队列(分母)的总生存差异有统计学意义(p=0.000353)。
- 仅11%的研究报告了分母描述,作者认为发表结局应常规纳入报告中心管理的所有女性结局。
核心结论
- 分母数据对理解晚期卵巢癌的选择和总生存至关重要。
- 已发表的选择性队列结局应常规纳入报告中心管理的所有女性结局。
- 作者认为这对妇科癌症的基准制定和质量保证必不可少,应成为任何晚期卵巢癌结局发表的一部分。
研究设计与样本
- 回顾性综述区域癌症中心77个月内诊断的593例晚期卵巢癌患者的总生存结局。
- 按治疗情况将患者分为五个逐步重叠的类别:初次减瘤术(PDS)、PDS或间隔减瘤术(IDS)、所有手术及考虑IDS者、接受任何治疗者、总患者队列。
- 进行了系统文献检索。
主要发现
- 中位总生存从接受PDS患者的54.5个月,降至PDS+IDS组的38.7个月、PDS/IDS+考虑IDS患者的35.4个月、接受任何治疗者的33.3个月、总患者队列的30.2个月。
- 手术组与总患者队列(分母)的总生存差异有统计学意义(p=0.000353)。
- 文献中仅11%的研究报告了分母描述。
临床怎么用
- 作者认为已发表的选择性队列结局应常规纳入报告中心管理的所有女性结局,以用于妇科癌症的基准制定和质量保证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Combined surgery and platinum-based chemotherapy is the internationally agreed standard therapy for advanced ovarian cancer (AOC). However international cancer registry datasets demonstrate a significant proportion of patients do not receive both or either therapies. Our objective was to evaluate the effect of total patient cohort data ('Denominator') on median overall survival (OS) and determine how frequently this was reported in literature. METHODS: We retrospectively reviewed OS outcomes for 593 patients diagnosed with AOC for 77 months at a regional cancer centre. Patients were stratified into five progressively overlapping categories based on treatment received - Primary debulking surgery (PDS), PDS or Interval debulking (IDS), all surgery and those considered for IDS, patients receiving any treatment and total patient cohort. A systematic search of literature was performed. RESULTS: Median OS progressively decreased from 54.5 months in patients receiving PDS, 38.7 months in the PDS+IDS group, 35.4 months in the PDS/IDS+patients considered for IDS, 33.3 months in patients receiving any treatment and 30.2 months in the total patient cohort. OS in the surgically treated group was statistically significantly different from the OS in the total patient cohort (Denominator)(p=0.000353). Denominator descriptors were identified in 11% of studies. CONCLUSIONS: Denominator data is critical to understanding selection and OS in AOC. Published outcomes of selected cohorts should routinely incorporate outcomes for all women managed within the reporting Centre. This is essential for benchmarking and quality assurance in gynaecological cancer and should be an integral part of any publication on outcomes from AOC.
引用
- Phillips A, Balega J, Nevin J, et al. Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017. PMID: 28411948. doi:10.1016/j.ygyno.2017.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。